Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of Repeat-Dose Rifampin Effect on PF-06651600 PK in Healthy Participants
NCT04266509Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Jun 2020; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04266509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266509.